PUBLIC HEALTH INSTITUTE (PHI)

Funding Organization

Awards Grant

  • A Phase 1, Open-Label, Dose-escalation trial of CD33xCD3 Bispecific Antibody in Pediatric patients with Relapsed of Refractory Acute Myeloid Leukemia - COG ADVL 2111
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
  • AAML1831A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations”
  • ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”
  • APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
  • ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat(PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors -AR10441
  • An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
  • COG Nursing Committee
  • COG Scientific Council
  • COG Scientific Council
  • Cancer Care Delivery Study Chair
  • Children's Oncology Group NCTN Network Group Operations
  • Children's Oncology Group NCTN Network Group Operations
  • Children's Oncology Group NCTN Network Group Operations
  • Improving the Reach and Effectiveness of STD Prevention, Screening, and Treatment Services in Local Public Health Systems
  • Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823
  • Long-term Follow-up Center to Facilitate Survivorship Research within COG
  • NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
  • PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
  • PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955 -PHI/COG
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
  • Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG
  • Workload Intensity NIH Nationl Clinical Trials Network (NCTN) Grant (U10DA180886) - PHI/COG
  • Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG